F8 and hemarthrosis: Taken together, results of clinical and pre-clinical studies would suggest that even though danger signals are often present at the time of FVIII administration (e.g., hemarthrosis), this does not always determine the occurrence of an immunogenic response to FVIII but can also allow the development of tolerance through the upregulation of systems of adaptive immunity that actively promote tolerance and control inflammation (Figure 2).